Table 4.
Normolipidemic human blood LDL (0.25 mg/mL) in vitro oxidation in the presence of 5 μM CuSO4 and CA of 3 types (DHPs, verapamil, and diltiazem) and vitamin E. Compiled according to Lupo et al. [129].
| Compound | Methods | |||
|---|---|---|---|---|
| TBARS method (fluorimetry at 515 nm/533 nm, 4 hours preincubation of LDL with compounds and copper (II) ions; 320% TBARS increase in control during 4 h period) |
Inhibition of conjugated diene formation (at 234 nm) expressed as prolongation of induction period (in %% of control). t contr = 36.8 min. |
|||
| Effective [IC] (in μM): 1 μM; 10 μM; 50 μM |
Activity rank order (ARO = I for the highest activity; ARO = VII for the mindest activity) | Effective [IC] (in μM): 1 μM; 5 μM; 10 μM; 50 μM |
Activity rank order (ARO = I for the highest activity; ARO = VII for the mindest activity) | |
| Nifedipine | 10 μM; 50 μM |
ARO = III | 5 μM; 10 μM, 150%; 50 μM, 213% |
ARO = III |
| Amlodipine | 50 μM | ARO = IV | 5 μM; 10 μM, 122%; 50 μM, 138% |
ARO = IV–VI |
| Isradipine | 50 μM | ARO = VI | 10 μM, 150%; 50 μM, 183% |
ARO = IV–VI |
| Lacidipine | 1 μM; 10 μM; 50 μM |
ARO = II | 5 μM; 10 μM, 192%; 50 μM, 283% |
ARO = II |
| Verapamil | 50 μM | ARO = V | 10 μM, 150%; 50 μM, 178% |
ARO = IV–VI |
| Diltiazem | No effect | No effect (ARO = VII) | No effect | No effect (ARO = VII) |
| Vitamin E | 1 μM; 10 μM (IC50); 50 μM (20% of control) |
ARO = I | 5 μM; 10 μM, 230%; 50 μM, 370% |
ARO = I |